



63-20-032

1635

Express Mail No.: EV 188 777 143 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: John C. Reed

Confirmation No.: 5198

Serial No.: 09/375,514

Art Unit: 1635

Filed: August 17, 1999

Examiner: Schmidt, M.

For: REGULATION OF BCL-2 GENE
EXPRESSION

Attorney Docket No: 10412-011

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 27 2003

TECH CENTER 1600/2900

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$216.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)0			(Col. 2)	(Col. 3)	<input type="checkbox"/> SMALL ENTITY			<input checked="" type="checkbox"/> OTHER THAN A SMALL ENTITY		
CLAIMS REMAINING AFTER AMENDMENT			HIGHEST NO. PREVIOUSLY PAID	PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE	
TOTAL	48	MINUS	36	12	x 9	\$		x 18	\$ 216.00	
INDEP.	3	MINUS	6	0	x 42	\$		x 84	\$ 0.00	
						\$		\$	0.00	
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					TOTAL	\$	OR	TOTAL	\$ 54.00	

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.
A copy of this sheet is enclosed.

Date: March 18, 2003

Respectfully submitted

by *Jacqueline Penn*
Laura A. Coruzzi

Reg No. 43,492

30,742

Laura A. Coruzzi

(Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

Enclosure



Express Mail No: EV 188 777 143 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: John C. Reed

Serial No.: 09/375,514

Filed: August 17, 1999

For: REGULATION OF BCL-2 GENE
EXPRESSION

Group Art Unit: 1635

Examiner: Schmidt, M.

Attorney Docket No.: 10412-011

#26/F
Zita
3/28/03

AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 27 2003

TECH CENTER 1600/2900

Sir:

In response to the Office Action dated December 18, 2002, and pursuant to Rule 111 of the Rules of Practice, please consider the following amendments and remarks.

Applicant submits herewith: 1) an Amendment Fee Transmittal Sheet, 2) a copy of the claims that will be pending upon entry of this amendment, attached hereto as Exhibit A; and 3) a copy of Tsujimoto and Croce, 1986, Proc. Natl. Acad. Sci. USA 83:5214-5218 (disclosed in Information Disclosure Statement filed November 17, 1999), attached hereto as Exhibit B.

IN THE CLAIMS:

Please cancel claims 54 to 69, without prejudice.

Please add new claims 70 to 88 as follows:

70. (New) An anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary to a portion of SEQ ID NO:19.

71. (New) An anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary to a portion of SEQ ID NO:22.

72. (New) The anticode oligomer of Claim 70, wherein said anticode oligomer is an antisense oligonucleotide complementary to a splice acceptor site of SEQ ID NO:19.

03/25/2003 JBALINAN 00000141 161150 09375514

01 FC:1202

216.00 CH

Doc #: NY2: 1397429.1